Article(id=1326652135657287764, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652135099445330, articleNumber=null, orderNo=null, doi=10.13683/j.wph.2025.09.001, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1734364800000, receivedDateStr=2024-12-17, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794228117145, onlineDateStr=2026-11-09, pubDate=1757433600000, pubDateStr=2025-09-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794228117145, onlineIssueDateStr=2026-11-09, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794228117145, creator=13701087609, updateTime=1794228117145, updator=13701087609, issue=Issue{id=1326652135099445330, tenantId=1146029695717560320, journalId=1319690329412173987, year='2025', volume='46', issue='9', pageStart='869', pageEnd='998', issueExtLink='null', onlineDate='null', pubDate='1757433600000', pubDateStr='2025-09-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794228117011, creator='13701087609', updateTime=1794272950571, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1326840181111501690, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652135099445330, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1326840181111501691, tenantId=1146029695717560320, journalId=1319690329412173987, issueId=1326652135099445330, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=869, endPage=877, ext={EN=ArticleExt(id=1326652135929917525, articleId=1326652135657287764, tenantId=1146029695717560320, journalId=1319690329412173987, language=EN, title=Advances in the application of biologics and molecular targeted drugs in hidradenitis suppurativa with comorbidities, columnId=1325221107665612978, journalTitle=World Clinical Drug, columnName=Topic, runingTitle=null, highlight=null, articleAbstract=

Hidradenitis suppurative(HS) is a chronic, recurrent skin disease of follicular inflammatory, accompanied by multiple comorbidities. At present, the pathogenesis of HS remains unclear, with activation of innate immune system and various inflammatory cytokines. In recent years, biological agents and molecular targeted drugs targeting these targets have shown certain efficacy and application prospects for HS. This article reviewed the clinical research progress of different biologics and molecular targeted drugs in the treatment of HS and HS with comorbidities.

, authors=Xinyi XU, Qian ZHAO, Xiaohui MO, Qiang JU*, authorsList=Xinyi XU, Qian ZHAO, Xiaohui MO, Qiang JU, authorCompany=null, correspAuthors=Qiang JU, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1326652136223518806, articleId=1326652135657287764, tenantId=1146029695717560320, journalId=1319690329412173987, language=CN, title=生物制剂及分子靶向药物治疗化脓性汗腺炎及其共病的临床研究进展, columnId=1325221107824996532, journalTitle=世界临床药物, columnName=医药专论, runingTitle=null, highlight=null, articleAbstract=

化脓性汗腺炎(hidradenitis suppurative,HS)是一种慢性、反复发作的毛囊炎症性皮肤病,且伴随多种共病存在。HS发生机制目前仍不明确,天然免疫系统激活及多种炎性细胞因子参与其中。近年来,针对这些靶点的生物制剂及分子靶向药物对HS显示出一定疗效和应用前景。该文就不同靶点生物制剂及分子靶向药物治疗HS及其共病的临床研究进展作一综述。

, authors=徐心怡, 赵茜, 莫小辉, 鞠强*, authorsList=徐心怡, 赵茜, 莫小辉, 鞠强, authorCompany=null, correspAuthors=鞠强, authorNote=

徐心怡,博士研究生,研究方向:化脓性汗腺炎。

, correspAuthorsNote=
鞠强,主任医师,研究方向:化脓性汗腺炎、痤疮。
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=Imhg3iLlsP3IRczkvivGhw==, magXml=yre+V82jlf5vl5ZVLIEbpg==, pdfUrl=null, pdf=Zyu110olqpx0ZXwLArBBKA==, pdfFileSize=999571, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=4XKF2LVZn2OUA8G+roajEA==, mapNumber=null, fund=null)}, authors=[Author(id=1326652136538091611, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652136613589085, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652136538091611, language=EN, stringName=Xinyi XU, firstName=Xinyi, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652136672309342, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652136538091611, language=CN, stringName=徐心怡, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海交通大学医学院附属仁济医院皮肤科,上海 200127, bio={"content":"

徐心怡,博士研究生,研究方向:化脓性汗腺炎。

"}, bioImg=null, bioContent=

徐心怡,博士研究生,研究方向:化脓性汗腺炎。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652136458399831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, xref=null, ext=[AuthorCompanyExt(id=1326652136466788440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China), AuthorCompanyExt(id=1326652136475177049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属仁济医院皮肤科,上海 200127)])]), Author(id=1326652136752001120, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652136827498594, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652136752001120, language=EN, stringName=Qian ZHAO, firstName=Qian, middleName=null, lastName=ZHAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652136894607459, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652136752001120, language=CN, stringName=赵茜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海交通大学医学院附属仁济医院皮肤科,上海 200127, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652136458399831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, xref=null, ext=[AuthorCompanyExt(id=1326652136466788440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China), AuthorCompanyExt(id=1326652136475177049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属仁济医院皮肤科,上海 200127)])]), Author(id=1326652136961716325, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652137045602407, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652136961716325, language=EN, stringName=Xiaohui MO, firstName=Xiaohui, middleName=null, lastName=MO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652137133682792, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652136961716325, language=CN, stringName=莫小辉, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海交通大学医学院附属仁济医院皮肤科,上海 200127, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652136458399831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, xref=null, ext=[AuthorCompanyExt(id=1326652136466788440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China), AuthorCompanyExt(id=1326652136475177049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属仁济医院皮肤科,上海 200127)])]), Author(id=1326652137213374570, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652137301454956, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652137213374570, language=EN, stringName=Qiang JU, firstName=Qiang, middleName=null, lastName=JU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652137393729645, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652137213374570, language=CN, stringName=鞠强, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=上海交通大学医学院附属仁济医院皮肤科,上海 200127, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652136458399831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, xref=null, ext=[AuthorCompanyExt(id=1326652136466788440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China), AuthorCompanyExt(id=1326652136475177049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属仁济医院皮肤科,上海 200127)])])], keywords=[Keyword(id=1326652137536335982, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, language=EN, orderNo=1, keyword=hidradenitis suppurativa), Keyword(id=1326652137620222063, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, language=EN, orderNo=2, keyword=acne inversa), Keyword(id=1326652137695719536, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, language=EN, orderNo=3, keyword=biologics), Keyword(id=1326652139360858225, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, language=EN, orderNo=4, keyword=molecular targeted drug), Keyword(id=1326652139440550002, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, language=EN, orderNo=5, keyword=comorbidity), Keyword(id=1326652139503464563, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, language=CN, orderNo=1, keyword=化脓性汗腺炎), Keyword(id=1326652139562184820, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, language=CN, orderNo=2, keyword=反常性痤疮), Keyword(id=1326652139671236725, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, language=CN, orderNo=3, keyword=生物制剂), Keyword(id=1326652139788677238, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, language=CN, orderNo=4, keyword=分子靶向药物), Keyword(id=1326652139859980407, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, language=CN, orderNo=5, keyword=共病)], refs=[Reference(id=1326652140052918393, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG ZS, LI J, JU Q, et al. Prevalence of acne inversa(hidradenitis suppurativa) in China: a nationwide cross-sectional epidemiological study[J]. Int J Dermatol Venereol, 2022, 5(1): 1-7., articleTitle=null, refAbstract=null), Reference(id=1326652140115832954, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=SAUNTE DML, JEMEC GBE. Hidradenitis suppurativa:advances in diagnosis and treatment[J]. J Am Med Assoc, 2017, 318(20): 2019-2032., articleTitle=null, refAbstract=null), Reference(id=1326652140208107643, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=GOLDBURG SR, STROBER BE, PAYETTE MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis[J]. J Am Acad Dermatol, 2020, 82(5):1045-1058., articleTitle=null, refAbstract=null), Reference(id=1326652140275216508, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=王慧, 黄贺, 张学军, 等. 生物制剂在化脓性汗腺炎治疗中的应用进展[J]. 中国皮肤性病学杂志, 2022, 36(2): 218-221., articleTitle=null, refAbstract=null), Reference(id=1326652140342325373, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=YOUNG AT, LU K, DAI A, et al. Infliximab shows superior drug survival among biologics for hidradenitis suppurativa: a cohort study[J]. J Am Acad Dermatol, 2025, 92(1): 139-141., articleTitle=null, refAbstract=null), Reference(id=1326652140417822846, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=PRENS LM, BOUWMAN K, AARTS P, et al. Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study[J]. Br J Dermatol, 2021, 185(1): 177-184., articleTitle=null, refAbstract=null), Reference(id=1326652140480737407, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=GRANT A, GONZALEZ T, MONTGOMERY MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial[J]. J Am Acad Dermatol, 2010, 62(2): 205-217., articleTitle=null, refAbstract=null), Reference(id=1326652140539457664, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=MONTAUDIE H, SEITZ-POLSKI B, CORNILLE A, et al. Interleukin 6 and high-sensitivity C-reactive protein are potential predictive markers of response to infliximab in hidradenitis suppurativa[J]. J Am Acad Dermatol, 2017,76(1): 156-158., articleTitle=null, refAbstract=null), Reference(id=1326652140598177921, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=FREW JW, GRAND G, NAVRAZHINA K, et al. Assessing the responsiveness of sonographic biomarkers to brodalumab therapy in hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2021, 35(12): e884-e887., articleTitle=null, refAbstract=null), Reference(id=1326652140665286786, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=NAVRAZHINA K, FREW JW, GRAND D, et al. Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum[J]. Br J Dermatol, 2022, 187(2): 223-233., articleTitle=null, refAbstract=null), Reference(id=1326652140719812739, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=JEMEC GBE, OKUN MM, FORMAN SB, et al. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phaseⅢ randomized placebo-controlled PIONEER trials[J]. Br J Dermatol, 2019, 181(5): 967-975., articleTitle=null, refAbstract=null), Reference(id=1326652140778532996, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=ZOUBOULIS CC, OKUN MM, PRENS EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study[J]. J Am Acad Dermatol, 2019, 80(1): 60-69., articleTitle=null, refAbstract=null), Reference(id=1326652140841447557, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=GARBAYO-SALMONS P, VILARRASA E, BASSAS-VILA J, et al. Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2025, 39(1): 221-229., articleTitle=null, refAbstract=null), Reference(id=1326652140904362118, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=AARTS P, VAN HUIJSTEE JC, VAN DER ZEE HH, et al. Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: a randomized controlled trial in a real-world setting[J]. J Am Acad Dermatol, 2023, 89(4): 677-684., articleTitle=null, refAbstract=null), Reference(id=1326652140975665287, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=BECHARA FG, PODDA M, PRENS EP, et al. Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa[J]. J Am Med Assoc Surgery, 2021, 156(11): 1001-1009., articleTitle=null, refAbstract=null), Reference(id=1326652141038579848, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=AARTS P, VAN HUIJSTEE JC, VAN DER ZEE HH, et al. Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2024, 38(5):904-909., articleTitle=null, refAbstract=null), Reference(id=1326652141109883017, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=KRAJEWSKI PK, JFRI A, OCHANDO-IBERNON G, et al. Ultrasonographic railway sign in tunnels as a new independent risk factor of adalimumab failure in hidradenitis suppurativa[J]. J Am Acad Dermatol, 2023, 88(3): 732-734., articleTitle=null, refAbstract=null), Reference(id=1326652141172797578, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=SHIH T, LEE K, GROGAN T, et al. Infliximab in hidradenitis suppurativa: a systematic review and meta-analysis[J]. Dermatol Ther, 2022, 35(9): e15691., articleTitle=null, refAbstract=null), Reference(id=1326652141235712139, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=MACHET L, SAMIMI M, DELAGE M, et al. Systematic review of the efficacy and adverse events associated with infliximab treatment of hidradenitis suppurativa in patients with coexistent inflammatory diseases[J]. J Am Acad Dermatol, 2013, 69(4): 649-650., articleTitle=null, refAbstract=null), Reference(id=1326652141302821004, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=VAN RAPPARD DC, MOOIJ JE, BAETEN DLP, et al. New-onset polyarthritis during successful treatment of hidradenitis suppurativa with infliximab[J]. Br J Dermatol, 2011, 165(1):194-198., articleTitle=null, refAbstract=null), Reference(id=1326652141378318477, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=GHIAS MH, JOHNSTON AD, KUTNER AJ, et al. High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa[J]. J Am Acad Dermatol, 2020,82(5): 1094-1101., articleTitle=null, refAbstract=null), Reference(id=1326652141441233038, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=MORIARTY B, JIYAD Z, CREAMER D. Four-weekly infliximab in the treatment of severe hidradenitis suppurativa[J]. Br J Dermatol, 2014, 170(4): 986-987., articleTitle=null, refAbstract=null), Reference(id=1326652141520924815, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG LL, MICHELETTI RG. Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: a retrospective chart review[J]. J Am Acad Dermatol, 2020, 82(2): 507-510., articleTitle=null, refAbstract=null), Reference(id=1326652141604810896, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=LEE RA, DOMMASCH E, TREAT J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa[J]. J Am Acad Dermatol, 2009,60(4): 565-573., articleTitle=null, refAbstract=null), Reference(id=1326652141676114065, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=ZOUBOULIS CC, KYRGIDIS A, ALAVI A, et al. Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the international hidradenitis suppurativa severity score system(IHS4): a post hoc analysis of the SUNSHINE and SUNRISE trials[J]. J Eur Acad Dermatol Venereol, 2024,39(8): 1421-1430., articleTitle=null, refAbstract=null), Reference(id=1326652141751611538, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=ZOUBOULIS CC, PASSERON T, PARISER D, et al. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase Ⅲtrials[J]. Br J Dermatol, 2024, 190(6): 836-845., articleTitle=null, refAbstract=null), Reference(id=1326652141810331795, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=KIMBALL AB, JEMEC GBE, ALAVI A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa(SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials[J]. Lancet, 2023, 401(10378):747-761., articleTitle=null, refAbstract=null), Reference(id=1326652141873246356, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=MELGOSA RAMOS FJ, GARCIA RUIZ R, ESTEBANEZ CORRALES A, et al. Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: a retrospective single-centre case series(23 patients)[J]. J Eur Acad Dermatol Venereol, 2022, 37(4): e517-e519., articleTitle=null, refAbstract=null), Reference(id=1326652141948743829, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=HASELGRUBER S, FERNANDEZ-CREHUET-SERRANO P, FERNANDEZ-BALLESTEROS MD, et al. Insights into the window of opportunity and outcome measures in patients with moderate to severe hidradenitis suppurativa treated with secukinumab: a real-world study[J]. Dermatol Ther, 2024,14(7): 1875-1890., articleTitle=null, refAbstract=null), Reference(id=1326652142011658390, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=RIBERO S, RAMONDETTA A, FABBROCINI G, et al. Effectiveness of secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting[J]. J Eurn Acad Dermatol Venereol, 2021, 35(7): e441-e442., articleTitle=null, refAbstract=null), Reference(id=1326652142078767255, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=MOLINELLI E, SIMONETTI O. Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa[J]. Lancet, 2024, 403(10443):2457-2459., articleTitle=null, refAbstract=null), Reference(id=1326652142141681816, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=KIMBALL AB, JEMEC GBE, SAYED CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa(BE HEARD Ⅰ and BE HEARDⅡ): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials[J]. Lancet, 2024,403(10443): 2504-2519., articleTitle=null, refAbstract=null), Reference(id=1326652143806820506, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=URENA-PANIEGO C, HASELGRUBER S, SOTO-MORENO A, et al. Eligibility in a cohort of patients with hidradenitis suppurativa treated with bimekizumab: lessons and pitfalls in a real-world setting[J]. J Eur Acad Dermatol Venereol, 2024, 38(9): e823-e824., articleTitle=null, refAbstract=null), Reference(id=1326652144058478747, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=MEGNA M, RUGGIERO A, DI GUIDA A, et al. Ixekizumab:an efficacious treatment for both psoriasis and hidradenitis suppurativa[J]. Dermatol Ther, 2020, 33(4): e13756., articleTitle=null, refAbstract=null), Reference(id=1326652144163336348, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=FREW JW, NAVRAZHINA K, GRAND D, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study[J]. J Am Acad Dermatol, 2020, 83(5): 1341-1348., articleTitle=null, refAbstract=null), Reference(id=1326652144272388254, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=FREW JW, NAVRAZHINA K, SULLIVAN-WHALEN M, et al. Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study[J]. Br J Dermatol, 2021, 184(2): 350-352., articleTitle=null, refAbstract=null), Reference(id=1326652144335302815, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=OSORIO-GOMEZ GF, ORTIZ-ALVAREZ J, DIAZ-CECA D, et al. Brodalumab for moderate–severe hidradenitis suppurativa: An open-label multicentric cohort study in real clinical practice[J]. Australas J Dermatol, 2024, 65(3): 254-259., articleTitle=null, refAbstract=null), Reference(id=1326652144406605984, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=MASSON R, SEIVRIGHT J, GROGAN T, et al. Ustekinumab in hidradenitis suppurativa: a systematic review and meta-analysis[J]. Dermatol Ther(Heidelb), 2024, 14(7):1901-1916., articleTitle=null, refAbstract=null), Reference(id=1326652144461131937, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=MONTERO-VILCHEZ T, POZO-ROMAN T, SANCHEZ-VELICIA L, et al. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review[J]. J Dermatolog Treat, 2020, 33(1): 348-353., articleTitle=null, refAbstract=null), Reference(id=1326652144536629410, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=JIANG SW, KWOCK JT, LIU BY, et al. High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa[J]. Br J Dermatol, 2022, 187(3):417-419., articleTitle=null, refAbstract=null), Reference(id=1326652144599543971, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=DUDINK K, BOUWMAN K, CHEN YQ, et al. Guselkumab for hidradenitis suppurativa: a phase Ⅱ, open-label, mode-of-action study[J]. Br J Dermatol, 2023, 188(5): 601-609., articleTitle=null, refAbstract=null), Reference(id=1326652144683430052, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=KIMBALL AB, PODDA M, ALAVI A, et al. Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: a phase 2 randomized study[J]. J Eur Acad Dermatol Venereol, 2023, 37(10): 2098-2108., articleTitle=null, refAbstract=null), Reference(id=1326652144758927525, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=MELGOSA RAMOS FJ, GARCIA RUIZ R, MATEU PUCHADES A, et al. Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: a retrospective bicentric experience[J]. Dermatol Ther, 2022, 35(7): e15558., articleTitle=null, refAbstract=null), Reference(id=1326652144838619302, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=GOTTLIEB A, NATSIS NE, KERDEL F, et al. A phase Ⅱopen-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain[J]. J Invest Dermatol, 2020, 140(8): 1538-1545., articleTitle=null, refAbstract=null), Reference(id=1326652144909922471, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=HOURIET C, JAFARI SMS, THOMI R, et al. Canakinumab for severe hidradenitis suppurativa: preliminary experience in 2 cases[J]. J Am Med Assoc Dermatol, 2017, 153(11): 1195-1197., articleTitle=null, refAbstract=null), Reference(id=1326652144981225640, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=JAEGER T, ANDRES C, GROSBER M, et al. Pyoderma gangrenosum and concomitant hidradenitis suppurativa –rapid response to canakinumab(anti-IL-1β)[J]. Eur J Dermatol, 2013, 23(3): 408-410., articleTitle=null, refAbstract=null), Reference(id=1326652145056723113, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=AKDOGAN N, YALICI-ARMAGAN B, DOGAN S, et al. Severe hidradenitis suppurativa(acne inversa) associated with focal segmental glomerulosclerosis and gout partially responsive to canakinumab[J]. Dermatol Ther, 2021, 34(4):edth15002., articleTitle=null, refAbstract=null), Reference(id=1326652145136414890, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=TZANETAKOU V, KANNI T, GIATRAKOU S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa[J].J Am Med Assoc Dermatol, 2016, 152(1): 52-59., articleTitle=null, refAbstract=null), Reference(id=1326652145224495275, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=LESLIE KS, TRIPATHI SV, NGUYEN TV, et al. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa[J]. J Am Acade Dermatol, 2014,70(2): 243-251., articleTitle=null, refAbstract=null), Reference(id=1326652145295798444, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=ALAVI A, PRENS EP, KIMBALL AB, et al. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial[J]. Br J Dermatol, 2024, 191(4): 508-518., articleTitle=null, refAbstract=null), Reference(id=1326652145400656045, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=GIAMARELLOS-BOURBOULIS EJ, ARGYROPOULOU M, KANNI T, et al. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab[J]. Br J Dermatol, 2020, 183(1): 176-178., articleTitle=null, refAbstract=null), Reference(id=1326652145476153518, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[52], rfOrder=51, authorNames=null, journalName=null, refType=null, unstructuredReference=MULLER S, ZEIDLER C, STANDER S. Chronic prurigo including prurigo nodularis: new insights and treatments[J]. Am J Clin Dermatol, 2023, 25(1): 15-33., articleTitle=null, refAbstract=null), Reference(id=1326652145551650991, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[53], rfOrder=52, authorNames=null, journalName=null, refType=null, unstructuredReference=PANDYA AG, EZZEDINE K, PASSERON T, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study[J]. J Am Acad Dermatol, 2025, doi: 10.1016/j.jaad.2025.06.027., articleTitle=null, refAbstract=null), Reference(id=1326652145622954160, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[54], rfOrder=53, authorNames=null, journalName=null, refType=null, unstructuredReference=KIRBY JS, OKUN MM, ALAVI A, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib(INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study[J]. J Am Acad Dermatol, 2024, 90(3): 521-529., articleTitle=null, refAbstract=null), Reference(id=1326652145744588977, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[55], rfOrder=54, authorNames=null, journalName=null, refType=null, unstructuredReference=LIU HQ, SANTOS LL, SMITH SH. Modulation of disease-associated pathways in hidradenitis suppurativa by the Janus kinase 1 inhibitor povorcitinib: transcriptomic and proteomic analyses of two phase 2 studies[J]. Int J Mol Sci, 2023, 24(8): 7185., articleTitle=null, refAbstract=null), Reference(id=1326652145841057970, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[56], rfOrder=55, authorNames=null, journalName=null, refType=null, unstructuredReference=KOZERA E, FLORA A, FREW JW. Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: a retrospective cohort study[J]. J Am Acade Dermatol, 2022, 87(6): 1440-1442., articleTitle=null, refAbstract=null), Reference(id=1326652145924944052, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[57], rfOrder=56, authorNames=null, journalName=null, refType=null, unstructuredReference=BEN ABDALLAH H, BREGNHOJ A, EMMANUEL T, et al. Efficacy and safety of the heat shock protein 90 inhibitor RGRN-305 in hidradenitis suppurativa[J]. J Am Med Assoc Dermatol, 2024, 160(1): 63-70., articleTitle=null, refAbstract=null), Reference(id=1326652146008830133, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[58], rfOrder=57, authorNames=null, journalName=null, refType=null, unstructuredReference=VOSSEN ARJV, VAN DOORN MBA, VAN DER ZEE HH, et al. Apremilast for moderate hidradenitis suppurativa:results of a randomized controlled trial[J]. J Am Acad Dermatol, 2019, 80(1): 80-88., articleTitle=null, refAbstract=null), Reference(id=1326652146084327606, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[59], rfOrder=58, authorNames=null, journalName=null, refType=null, unstructuredReference=AARTS P, VOSSEN ARJV, VAN DER ZEE HH, et al. Long-term treatment with apremilast in hidradenitis suppurativa:a 2-year follow-up of initial responders[J]. J Am Acad Dermatol, 2021, 85(1): 258-260., articleTitle=null, refAbstract=null), Reference(id=1326652146176602295, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[60], rfOrder=59, authorNames=null, journalName=null, refType=null, unstructuredReference=HUA VJ, KILGOUR JM, CHO HG, et al. Characterization of comorbidity heterogeneity among 13, 667 patients with hidradenitis suppurativa[J]. JCI Insight, 2021, 6(21):e151872., articleTitle=null, refAbstract=null), Reference(id=1326652146273071288, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[61], rfOrder=60, authorNames=null, journalName=null, refType=null, unstructuredReference=MILLER IM, ELLERVIK C, VINDING GR, et al. Association of metabolic syndrome and hidradenitis suppurativa[J]. J Am Med Assoc Dermatol, 2014, 150(12):1273-1280., articleTitle=null, refAbstract=null), Reference(id=1326652146344374457, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[62], rfOrder=61, authorNames=null, journalName=null, refType=null, unstructuredReference=EGEBERG A, GISLASON GH, HANSEN PR. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa[J]. J Am Med Assoc Dermatol, 2016, 152(4): 429-434., articleTitle=null, refAbstract=null), Reference(id=1326652146432454842, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[63], rfOrder=62, authorNames=null, journalName=null, refType=null, unstructuredReference=SMITH J, EZEKWE N, POURANG A, et al. Multifocal myositis and elevated creatine phosphokinase associated with the use of ustekinumab for hidradenitis suppurativa[J]. Br J Dermatol, 2021, 184(6): 1181-1182., articleTitle=null, refAbstract=null), Reference(id=1326652146499563707, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[64], rfOrder=63, authorNames=null, journalName=null, refType=null, unstructuredReference=CHEN WT, CHI CC. Association of hidradenitis suppurativa with inflammatory bowel disease: a systematic review and meta-analysis[J]. J Am Med Assoc Dermatol, 2019, 155(9):1022-1027., articleTitle=null, refAbstract=null), Reference(id=1326652146566672572, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[65], rfOrder=64, authorNames=null, journalName=null, refType=null, unstructuredReference=SCHNEEWEISS MC, MEROLA JF, SCHNEEWEISS S, et al. Risk of connective tissue disease, morphoea and systemic vasculitis in patients with hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2020, 35(1): 195-202., articleTitle=null, refAbstract=null), Reference(id=1326652146755416253, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[66], rfOrder=65, authorNames=null, journalName=null, refType=null, unstructuredReference=TANNENBAUM R, STRUNK A, GARG A. Overall and subgroup prevalence of pyoderma gangrenosum among patients with hidradenitis suppurativa: a population-based analysis in the United States[J]. J Am Acad Dermatol, 2019,80(6): 1533-1537., articleTitle=null, refAbstract=null), Reference(id=1326652148361834687, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[67], rfOrder=66, authorNames=null, journalName=null, refType=null, unstructuredReference=SCHNEEWEISS MC, KIM S, SCHNEEWEISS S, et al. Risk of inflammatory arthritis after a new diagnosis of hidradenitis suppurativa[J]. J Am Med Assoc Dermatol, 2020, 156(3):342-345., articleTitle=null, refAbstract=null), Reference(id=1326652148449915072, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[68], rfOrder=67, authorNames=null, journalName=null, refType=null, unstructuredReference=YOSHIDA Y, OYAMA N, IINO S, et al. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: a possible involvement of Th17 across the spectrum of both diseases[J].J Dermatol, 2021, 48(6): 916-920., articleTitle=null, refAbstract=null), Reference(id=1326652148575744193, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[69], rfOrder=68, authorNames=null, journalName=null, refType=null, unstructuredReference=BAERVELDT EM, KAPPEN JH, THIO HB, et al. Successful long-term triple disease control by ustekinumab in a patient with Behcet's disease, psoriasis and hidradenitis suppurativa:table 1[J]. Ann Rheum Dis, 2013, 72(4): 626-627., articleTitle=null, refAbstract=null), Reference(id=1326652148672213186, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[70], rfOrder=69, authorNames=null, journalName=null, refType=null, unstructuredReference=ABU RACHED N, GAMBICHLER T, OCKER L, et al. Upadacitinib treatment associated with varicella zoster infection complicated by haemophagocytic lymphohistiocytosis in a patient with severe hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2023, 38(2):e139-e141., articleTitle=null, refAbstract=null), Reference(id=1326652148735127747, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[71], rfOrder=70, authorNames=null, journalName=null, refType=null, unstructuredReference=OK MT, GOOGE PB, SAYED CJ, et al. The successful use of upadacitinib as monotherapy for hidradenitis suppurativa and ulcerative colitis in the setting of refractory disease[J]. Pediatr Dermatol, 2025, 42(2): 353-357., articleTitle=null, refAbstract=null), Reference(id=1326652148819013828, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[72], rfOrder=71, authorNames=null, journalName=null, refType=null, unstructuredReference=MACHADO MO, STERGIOPOULOS V, MAES M, et al. Depression and anxiety in adults with hidradenitis suppurativa:a systematic review and meta-analysis[J]. J Am Med Assoc Dermatol, 2019, 155(8): 939-945., articleTitle=null, refAbstract=null), Reference(id=1326652148877734085, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[73], rfOrder=72, authorNames=null, journalName=null, refType=null, unstructuredReference=GUNTER SJ, HOLCOMB ZE, LAM BD, et al. Hematologic abnormalities in patients with hidradenitis suppurativa receiving adalimumab[J]. J Am Med Assoc Dermatol, 2024,160(6): 678-681., articleTitle=null, refAbstract=null), Reference(id=1326652148940648646, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[74], rfOrder=73, authorNames=null, journalName=null, refType=null, unstructuredReference=ABU RACHED N, OCKER L, STOCKFLETH E, et al. Secukinumab is effective in a patient on haemodialysis for end-stage renal disease and severe hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2024, 38(9):e753-e754., articleTitle=null, refAbstract=null)], funds=[Fund(id=1326652139956449400, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, awardId=82373506, language=CN, fundingSource=国家自然科学基金面上项目(82373506), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1326652136458399831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, xref=null, ext=[AuthorCompanyExt(id=1326652136466788440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China), AuthorCompanyExt(id=1326652136475177049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属仁济医院皮肤科,上海 200127)])], figs=null, attaches=null, journal=Journal(id=1319689997550452896, delFlag=0, nameCn=世界临床药物, nameEn=World Clinical Drug, nameHistory1=null, nameHistory2=null, issn=1672-9188, eissn=null, cn=31-1939/R, coden=SLYHAA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=9c6IkcJKa1cF20h1u6lJeQ==, journalPrice=null, startedYear=null, abbrevIsoEn=World Clinical Drug, journalRemark=null, publicationField=null, createdTime=1792568214072, updatedTime=1792747519563, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=S, firstLetterEn=S, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=9c6IkcJKa1cF20h1u6lJeQ==, picEn=MRqUlTwfL6oqIHNy7eyFZQ==, jcr=null, cjcr=null, exts=[JournalExt(id=1320442059660570919, language=CN, name=世界临床药物, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519650, updatedTime=1792747519650, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1320442059723485480, language=EN, name=World Clinical Drug, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747519665, updatedTime=1792747519665, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=http://www.jwph.com.cn/journalx_sjlcyw/authorLogOn.action, submissionEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorLogOn.action, submissionReviewUrl=http://www.jwph.com.cn/journalx_sjlcyw/expertLogOn.action, submissionCeEditorUrl=http://www.jwph.com.cn/journalx_sjlcyw/editorInChiefLogOn.action, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1319690329412173987, websiteList=[Website(id=1321427104911179915, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/CN, language=CN, createTime=1792982372739, createBy=18614031015, updateTime=1792982514949, updateBy=18614031015, name=世界临床药物-中文, tplId=1146099689490845704, title=世界临床药物, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428428256031726, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=articleTextType, value=kx, createTime=1792982688249, updateTime=1792982688249, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428193117163, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982688234, updateTime=1792982688234, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428302169073, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=grayFlag, value=0, createTime=1792982688260, updateTime=1792982688260, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428172145642, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982688229, updateTime=1792982688229, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428327334899, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=minRunFlag, value=0, createTime=1792982688266, updateTime=1792982688266, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428226671597, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/file/pic, createTime=1792982688242, updateTime=1792982688242, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428314751986, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=silenceFlag, value=0, createTime=1792982688263, updateTime=1792982688263, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428209894380, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982688238, updateTime=1792982688238, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428268614639, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeColor, value=null, createTime=1792982688252, updateTime=1792982688252, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428428289586160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104911179915, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982688257, updateTime=1792982688257, creator=18614031015, updator=18614031015)]), Website(id=1321427104990871693, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690329412173987, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/sjlcyw/EN, language=EN, createTime=1792982372758, createBy=18614031015, updateTime=1792982556355, updateBy=18614031015, name=世界临床药物-英文, tplId=1146101810881728533, title=World Clinical Drug, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428446820021244, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=articleTextType, value=kx, createTime=1792982692675, updateTime=1792982692675, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446757106681, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=banner, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=RR/csUBcM48ejcuaaK5s0g==, createTime=1792982692660, updateTime=1792982692660, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447109428223, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=grayFlag, value=0, createTime=1792982692744, updateTime=1792982692744, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446736135160, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=logo, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic?fileId=yyY2emcxcV1CfIeK9tH8ZA==, createTime=1792982692655, updateTime=1792982692655, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447142981632, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=minRunFlag, value=0, createTime=1792982692752, updateTime=1792982692752, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446790661115, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/file/pic, createTime=1792982692668, updateTime=1792982692668, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447130399745, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=silenceFlag, value=0, createTime=1792982692749, updateTime=1792982692749, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446769689594, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982692663, updateTime=1792982692663, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428446832604157, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeColor, value=null, createTime=1792982692678, updateTime=1792982692678, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428447092651006, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1321427104990871693, code=themeStyle, value=.style-1 .main-menu ul>li { margin-right: 18px; } @media (max-width: 1442px) { .style-1 .main-menu ul>li a { font-size: 16px; padding: 10px 0; } }, createTime=1792982692740, updateTime=1792982692740, creator=18614031015, updator=18614031015)])], journalTitle=世界临床药物, weixinUrl=null, journalUrl=http://www.jwph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=World Clinical Drug, journalPhotoCn=9c6IkcJKa1cF20h1u6lJeQ==, journalPhotoEn=MRqUlTwfL6oqIHNy7eyFZQ==, journalFirstLetter=S, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.09.001, detailUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2025.09.001, pdfUrlCn=https://castjournals.cast.org.cn/joweb/sjlcyw/CN/PDF/10.13683/j.wph.2025.09.001, pdfUrlEn=https://castjournals.cast.org.cn/joweb/sjlcyw/EN/PDF/10.13683/j.wph.2025.09.001, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1757433600000, fullTextJson=null, articleText=null, reference=null)
收藏切换
生物制剂及分子靶向药物治疗化脓性汗腺炎及其共病的临床研究进展
徐心怡 , 赵茜 , 莫小辉 , 鞠强 *
世界临床药物 | 医药专论 2025,46(9): 869-877
收起
收藏切换
世界临床药物 |医药专论 2025 , 46 (9) : 869 -877
生物制剂及分子靶向药物治疗化脓性汗腺炎及其共病的临床研究进展
全屏
[Author(id=1326652136538091611, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652136613589085, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652136538091611, language=EN, stringName=Xinyi XU, firstName=Xinyi, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652136672309342, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652136538091611, language=CN, stringName=徐心怡, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海交通大学医学院附属仁济医院皮肤科,上海 200127, bio={"content":"

徐心怡,博士研究生,研究方向:化脓性汗腺炎。

"}, bioImg=null, bioContent=

徐心怡,博士研究生,研究方向:化脓性汗腺炎。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652136458399831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, xref=null, ext=[AuthorCompanyExt(id=1326652136466788440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China), AuthorCompanyExt(id=1326652136475177049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属仁济医院皮肤科,上海 200127)])]), Author(id=1326652136752001120, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652136827498594, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652136752001120, language=EN, stringName=Qian ZHAO, firstName=Qian, middleName=null, lastName=ZHAO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652136894607459, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652136752001120, language=CN, stringName=赵茜, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海交通大学医学院附属仁济医院皮肤科,上海 200127, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652136458399831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, xref=null, ext=[AuthorCompanyExt(id=1326652136466788440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China), AuthorCompanyExt(id=1326652136475177049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属仁济医院皮肤科,上海 200127)])]), Author(id=1326652136961716325, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1326652137045602407, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652136961716325, language=EN, stringName=Xiaohui MO, firstName=Xiaohui, middleName=null, lastName=MO, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652137133682792, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652136961716325, language=CN, stringName=莫小辉, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=上海交通大学医学院附属仁济医院皮肤科,上海 200127, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652136458399831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, xref=null, ext=[AuthorCompanyExt(id=1326652136466788440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China), AuthorCompanyExt(id=1326652136475177049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属仁济医院皮肤科,上海 200127)])]), Author(id=1326652137213374570, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1326652137301454956, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652137213374570, language=EN, stringName=Qiang JU, firstName=Qiang, middleName=null, lastName=JU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1326652137393729645, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, authorId=1326652137213374570, language=CN, stringName=鞠强, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=*, address=上海交通大学医学院附属仁济医院皮肤科,上海 200127, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1326652136458399831, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, xref=null, ext=[AuthorCompanyExt(id=1326652136466788440, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China), AuthorCompanyExt(id=1326652136475177049, tenantId=1146029695717560320, journalId=1319690329412173987, articleId=1326652135657287764, companyId=1326652136458399831, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=上海交通大学医学院附属仁济医院皮肤科,上海 200127)])])]
徐心怡, 赵茜, 莫小辉, 鞠强*
作者信息
  • 上海交通大学医学院附属仁济医院皮肤科,上海 200127
通讯作者:
鞠强,主任医师,研究方向:化脓性汗腺炎、痤疮。
作者简介:

徐心怡,博士研究生,研究方向:化脓性汗腺炎。

Advances in the application of biologics and molecular targeted drugs in hidradenitis suppurativa with comorbidities
Xinyi XU, Qian ZHAO, Xiaohui MO, Qiang JU*
Affiliations
  • Department of Dermatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China
出版时间: 2025-09-10 doi: 10.13683/j.wph.2025.09.001
文章导航
收藏切换

化脓性汗腺炎(hidradenitis suppurative,HS)是一种慢性、反复发作的毛囊炎症性皮肤病,且伴随多种共病存在。HS发生机制目前仍不明确,天然免疫系统激活及多种炎性细胞因子参与其中。近年来,针对这些靶点的生物制剂及分子靶向药物对HS显示出一定疗效和应用前景。该文就不同靶点生物制剂及分子靶向药物治疗HS及其共病的临床研究进展作一综述。

化脓性汗腺炎  /  反常性痤疮  /  生物制剂  /  分子靶向药物  /  共病

Hidradenitis suppurative(HS) is a chronic, recurrent skin disease of follicular inflammatory, accompanied by multiple comorbidities. At present, the pathogenesis of HS remains unclear, with activation of innate immune system and various inflammatory cytokines. In recent years, biological agents and molecular targeted drugs targeting these targets have shown certain efficacy and application prospects for HS. This article reviewed the clinical research progress of different biologics and molecular targeted drugs in the treatment of HS and HS with comorbidities.

hidradenitis suppurativa  /  acne inversa  /  biologics  /  molecular targeted drug  /  comorbidity
徐心怡, 赵茜, 莫小辉, 鞠强. 生物制剂及分子靶向药物治疗化脓性汗腺炎及其共病的临床研究进展. 世界临床药物, 2025 , 46 (9) : 869 -877 . DOI: 10.13683/j.wph.2025.09.001
Xinyi XU, Qian ZHAO, Xiaohui MO, Qiang JU. Advances in the application of biologics and molecular targeted drugs in hidradenitis suppurativa with comorbidities[J]. World Clinical Drug, 2025 , 46 (9) : 869 -877 . DOI: 10.13683/j.wph.2025.09.001
  • 国家自然科学基金面上项目(82373506)
参考文献 引证文献
排序方式:
[1]
WANG ZS, LI J, JU Q, et al. Prevalence of acne inversa(hidradenitis suppurativa) in China: a nationwide cross-sectional epidemiological study[J]. Int J Dermatol Venereol, 2022, 5(1): 1-7.
[2]
SAUNTE DML, JEMEC GBE. Hidradenitis suppurativa:advances in diagnosis and treatment[J]. J Am Med Assoc, 2017, 318(20): 2019-2032.
[3]
GOLDBURG SR, STROBER BE, PAYETTE MJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis[J]. J Am Acad Dermatol, 2020, 82(5):1045-1058.
[4]
王慧, 黄贺, 张学军, 等. 生物制剂在化脓性汗腺炎治疗中的应用进展[J]. 中国皮肤性病学杂志, 2022, 36(2): 218-221.
[5]
YOUNG AT, LU K, DAI A, et al. Infliximab shows superior drug survival among biologics for hidradenitis suppurativa: a cohort study[J]. J Am Acad Dermatol, 2025, 92(1): 139-141.
[6]
PRENS LM, BOUWMAN K, AARTS P, et al. Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study[J]. Br J Dermatol, 2021, 185(1): 177-184.
[7]
GRANT A, GONZALEZ T, MONTGOMERY MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial[J]. J Am Acad Dermatol, 2010, 62(2): 205-217.
[8]
MONTAUDIE H, SEITZ-POLSKI B, CORNILLE A, et al. Interleukin 6 and high-sensitivity C-reactive protein are potential predictive markers of response to infliximab in hidradenitis suppurativa[J]. J Am Acad Dermatol, 2017,76(1): 156-158.
[9]
FREW JW, GRAND G, NAVRAZHINA K, et al. Assessing the responsiveness of sonographic biomarkers to brodalumab therapy in hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2021, 35(12): e884-e887.
[10]
NAVRAZHINA K, FREW JW, GRAND D, et al. Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum[J]. Br J Dermatol, 2022, 187(2): 223-233.
[11]
JEMEC GBE, OKUN MM, FORMAN SB, et al. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phaseⅢ randomized placebo-controlled PIONEER trials[J]. Br J Dermatol, 2019, 181(5): 967-975.
[12]
ZOUBOULIS CC, OKUN MM, PRENS EP, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study[J]. J Am Acad Dermatol, 2019, 80(1): 60-69.
[13]
GARBAYO-SALMONS P, VILARRASA E, BASSAS-VILA J, et al. Real-world adalimumab survival and discontinuation factors in hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2025, 39(1): 221-229.
[14]
AARTS P, VAN HUIJSTEE JC, VAN DER ZEE HH, et al. Adalimumab in conjunction with surgery compared with adalimumab monotherapy for hidradenitis suppurativa: a randomized controlled trial in a real-world setting[J]. J Am Acad Dermatol, 2023, 89(4): 677-684.
[15]
BECHARA FG, PODDA M, PRENS EP, et al. Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa[J]. J Am Med Assoc Surgery, 2021, 156(11): 1001-1009.
[16]
AARTS P, VAN HUIJSTEE JC, VAN DER ZEE HH, et al. Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2024, 38(5):904-909.
[17]
KRAJEWSKI PK, JFRI A, OCHANDO-IBERNON G, et al. Ultrasonographic railway sign in tunnels as a new independent risk factor of adalimumab failure in hidradenitis suppurativa[J]. J Am Acad Dermatol, 2023, 88(3): 732-734.
[18]
SHIH T, LEE K, GROGAN T, et al. Infliximab in hidradenitis suppurativa: a systematic review and meta-analysis[J]. Dermatol Ther, 2022, 35(9): e15691.
[19]
MACHET L, SAMIMI M, DELAGE M, et al. Systematic review of the efficacy and adverse events associated with infliximab treatment of hidradenitis suppurativa in patients with coexistent inflammatory diseases[J]. J Am Acad Dermatol, 2013, 69(4): 649-650.
[20]
VAN RAPPARD DC, MOOIJ JE, BAETEN DLP, et al. New-onset polyarthritis during successful treatment of hidradenitis suppurativa with infliximab[J]. Br J Dermatol, 2011, 165(1):194-198.
[21]
GHIAS MH, JOHNSTON AD, KUTNER AJ, et al. High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa[J]. J Am Acad Dermatol, 2020,82(5): 1094-1101.
[22]
MORIARTY B, JIYAD Z, CREAMER D. Four-weekly infliximab in the treatment of severe hidradenitis suppurativa[J]. Br J Dermatol, 2014, 170(4): 986-987.
[23]
WANG LL, MICHELETTI RG. Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: a retrospective chart review[J]. J Am Acad Dermatol, 2020, 82(2): 507-510.
[24]
LEE RA, DOMMASCH E, TREAT J, et al. A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa[J]. J Am Acad Dermatol, 2009,60(4): 565-573.
[25]
ZOUBOULIS CC, KYRGIDIS A, ALAVI A, et al. Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the international hidradenitis suppurativa severity score system(IHS4): a post hoc analysis of the SUNSHINE and SUNRISE trials[J]. J Eur Acad Dermatol Venereol, 2024,39(8): 1421-1430.
[26]
ZOUBOULIS CC, PASSERON T, PARISER D, et al. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase Ⅲtrials[J]. Br J Dermatol, 2024, 190(6): 836-845.
[27]
KIMBALL AB, JEMEC GBE, ALAVI A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa(SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials[J]. Lancet, 2023, 401(10378):747-761.
[28]
MELGOSA RAMOS FJ, GARCIA RUIZ R, ESTEBANEZ CORRALES A, et al. Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: a retrospective single-centre case series(23 patients)[J]. J Eur Acad Dermatol Venereol, 2022, 37(4): e517-e519.
[29]
HASELGRUBER S, FERNANDEZ-CREHUET-SERRANO P, FERNANDEZ-BALLESTEROS MD, et al. Insights into the window of opportunity and outcome measures in patients with moderate to severe hidradenitis suppurativa treated with secukinumab: a real-world study[J]. Dermatol Ther, 2024,14(7): 1875-1890.
[30]
RIBERO S, RAMONDETTA A, FABBROCINI G, et al. Effectiveness of secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting[J]. J Eurn Acad Dermatol Venereol, 2021, 35(7): e441-e442.
[31]
MOLINELLI E, SIMONETTI O. Bimekizumab: dual inhibition as a promising tool in the management of hidradenitis suppurativa[J]. Lancet, 2024, 403(10443):2457-2459.
[32]
KIMBALL AB, JEMEC GBE, SAYED CJ, et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa(BE HEARD Ⅰ and BE HEARDⅡ): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials[J]. Lancet, 2024,403(10443): 2504-2519.
[33]
URENA-PANIEGO C, HASELGRUBER S, SOTO-MORENO A, et al. Eligibility in a cohort of patients with hidradenitis suppurativa treated with bimekizumab: lessons and pitfalls in a real-world setting[J]. J Eur Acad Dermatol Venereol, 2024, 38(9): e823-e824.
[34]
MEGNA M, RUGGIERO A, DI GUIDA A, et al. Ixekizumab:an efficacious treatment for both psoriasis and hidradenitis suppurativa[J]. Dermatol Ther, 2020, 33(4): e13756.
[35]
FREW JW, NAVRAZHINA K, GRAND D, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study[J]. J Am Acad Dermatol, 2020, 83(5): 1341-1348.
[36]
FREW JW, NAVRAZHINA K, SULLIVAN-WHALEN M, et al. Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study[J]. Br J Dermatol, 2021, 184(2): 350-352.
[37]
OSORIO-GOMEZ GF, ORTIZ-ALVAREZ J, DIAZ-CECA D, et al. Brodalumab for moderate–severe hidradenitis suppurativa: An open-label multicentric cohort study in real clinical practice[J]. Australas J Dermatol, 2024, 65(3): 254-259.
[38]
MASSON R, SEIVRIGHT J, GROGAN T, et al. Ustekinumab in hidradenitis suppurativa: a systematic review and meta-analysis[J]. Dermatol Ther(Heidelb), 2024, 14(7):1901-1916.
[39]
MONTERO-VILCHEZ T, POZO-ROMAN T, SANCHEZ-VELICIA L, et al. Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review[J]. J Dermatolog Treat, 2020, 33(1): 348-353.
[40]
JIANG SW, KWOCK JT, LIU BY, et al. High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa[J]. Br J Dermatol, 2022, 187(3):417-419.
[41]
DUDINK K, BOUWMAN K, CHEN YQ, et al. Guselkumab for hidradenitis suppurativa: a phase Ⅱ, open-label, mode-of-action study[J]. Br J Dermatol, 2023, 188(5): 601-609.
[42]
KIMBALL AB, PODDA M, ALAVI A, et al. Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: a phase 2 randomized study[J]. J Eur Acad Dermatol Venereol, 2023, 37(10): 2098-2108.
[43]
MELGOSA RAMOS FJ, GARCIA RUIZ R, MATEU PUCHADES A, et al. Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: a retrospective bicentric experience[J]. Dermatol Ther, 2022, 35(7): e15558.
[44]
GOTTLIEB A, NATSIS NE, KERDEL F, et al. A phase Ⅱopen-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain[J]. J Invest Dermatol, 2020, 140(8): 1538-1545.
[45]
HOURIET C, JAFARI SMS, THOMI R, et al. Canakinumab for severe hidradenitis suppurativa: preliminary experience in 2 cases[J]. J Am Med Assoc Dermatol, 2017, 153(11): 1195-1197.
[46]
JAEGER T, ANDRES C, GROSBER M, et al. Pyoderma gangrenosum and concomitant hidradenitis suppurativa –rapid response to canakinumab(anti-IL-1β)[J]. Eur J Dermatol, 2013, 23(3): 408-410.
[47]
AKDOGAN N, YALICI-ARMAGAN B, DOGAN S, et al. Severe hidradenitis suppurativa(acne inversa) associated with focal segmental glomerulosclerosis and gout partially responsive to canakinumab[J]. Dermatol Ther, 2021, 34(4):edth15002.
[48]
TZANETAKOU V, KANNI T, GIATRAKOU S, et al. Safety and efficacy of anakinra in severe hidradenitis suppurativa[J].J Am Med Assoc Dermatol, 2016, 152(1): 52-59.
[49]
LESLIE KS, TRIPATHI SV, NGUYEN TV, et al. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa[J]. J Am Acade Dermatol, 2014,70(2): 243-251.
[50]
ALAVI A, PRENS EP, KIMBALL AB, et al. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial[J]. Br J Dermatol, 2024, 191(4): 508-518.
[51]
GIAMARELLOS-BOURBOULIS EJ, ARGYROPOULOU M, KANNI T, et al. Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab[J]. Br J Dermatol, 2020, 183(1): 176-178.
[52]
MULLER S, ZEIDLER C, STANDER S. Chronic prurigo including prurigo nodularis: new insights and treatments[J]. Am J Clin Dermatol, 2023, 25(1): 15-33.
[53]
PANDYA AG, EZZEDINE K, PASSERON T, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study[J]. J Am Acad Dermatol, 2025, doi: 10.1016/j.jaad.2025.06.027.
[54]
KIRBY JS, OKUN MM, ALAVI A, et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib(INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study[J]. J Am Acad Dermatol, 2024, 90(3): 521-529.
[55]
LIU HQ, SANTOS LL, SMITH SH. Modulation of disease-associated pathways in hidradenitis suppurativa by the Janus kinase 1 inhibitor povorcitinib: transcriptomic and proteomic analyses of two phase 2 studies[J]. Int J Mol Sci, 2023, 24(8): 7185.
[56]
KOZERA E, FLORA A, FREW JW. Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: a retrospective cohort study[J]. J Am Acade Dermatol, 2022, 87(6): 1440-1442.
[57]
BEN ABDALLAH H, BREGNHOJ A, EMMANUEL T, et al. Efficacy and safety of the heat shock protein 90 inhibitor RGRN-305 in hidradenitis suppurativa[J]. J Am Med Assoc Dermatol, 2024, 160(1): 63-70.
[58]
VOSSEN ARJV, VAN DOORN MBA, VAN DER ZEE HH, et al. Apremilast for moderate hidradenitis suppurativa:results of a randomized controlled trial[J]. J Am Acad Dermatol, 2019, 80(1): 80-88.
[59]
AARTS P, VOSSEN ARJV, VAN DER ZEE HH, et al. Long-term treatment with apremilast in hidradenitis suppurativa:a 2-year follow-up of initial responders[J]. J Am Acad Dermatol, 2021, 85(1): 258-260.
[60]
HUA VJ, KILGOUR JM, CHO HG, et al. Characterization of comorbidity heterogeneity among 13, 667 patients with hidradenitis suppurativa[J]. JCI Insight, 2021, 6(21):e151872.
[61]
MILLER IM, ELLERVIK C, VINDING GR, et al. Association of metabolic syndrome and hidradenitis suppurativa[J]. J Am Med Assoc Dermatol, 2014, 150(12):1273-1280.
[62]
EGEBERG A, GISLASON GH, HANSEN PR. Risk of major adverse cardiovascular events and all-cause mortality in patients with hidradenitis suppurativa[J]. J Am Med Assoc Dermatol, 2016, 152(4): 429-434.
[63]
SMITH J, EZEKWE N, POURANG A, et al. Multifocal myositis and elevated creatine phosphokinase associated with the use of ustekinumab for hidradenitis suppurativa[J]. Br J Dermatol, 2021, 184(6): 1181-1182.
[64]
CHEN WT, CHI CC. Association of hidradenitis suppurativa with inflammatory bowel disease: a systematic review and meta-analysis[J]. J Am Med Assoc Dermatol, 2019, 155(9):1022-1027.
[65]
SCHNEEWEISS MC, MEROLA JF, SCHNEEWEISS S, et al. Risk of connective tissue disease, morphoea and systemic vasculitis in patients with hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2020, 35(1): 195-202.
[66]
TANNENBAUM R, STRUNK A, GARG A. Overall and subgroup prevalence of pyoderma gangrenosum among patients with hidradenitis suppurativa: a population-based analysis in the United States[J]. J Am Acad Dermatol, 2019,80(6): 1533-1537.
[67]
SCHNEEWEISS MC, KIM S, SCHNEEWEISS S, et al. Risk of inflammatory arthritis after a new diagnosis of hidradenitis suppurativa[J]. J Am Med Assoc Dermatol, 2020, 156(3):342-345.
[68]
YOSHIDA Y, OYAMA N, IINO S, et al. Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: a possible involvement of Th17 across the spectrum of both diseases[J].J Dermatol, 2021, 48(6): 916-920.
[69]
BAERVELDT EM, KAPPEN JH, THIO HB, et al. Successful long-term triple disease control by ustekinumab in a patient with Behcet's disease, psoriasis and hidradenitis suppurativa:table 1[J]. Ann Rheum Dis, 2013, 72(4): 626-627.
[70]
ABU RACHED N, GAMBICHLER T, OCKER L, et al. Upadacitinib treatment associated with varicella zoster infection complicated by haemophagocytic lymphohistiocytosis in a patient with severe hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2023, 38(2):e139-e141.
[71]
OK MT, GOOGE PB, SAYED CJ, et al. The successful use of upadacitinib as monotherapy for hidradenitis suppurativa and ulcerative colitis in the setting of refractory disease[J]. Pediatr Dermatol, 2025, 42(2): 353-357.
[72]
MACHADO MO, STERGIOPOULOS V, MAES M, et al. Depression and anxiety in adults with hidradenitis suppurativa:a systematic review and meta-analysis[J]. J Am Med Assoc Dermatol, 2019, 155(8): 939-945.
[73]
GUNTER SJ, HOLCOMB ZE, LAM BD, et al. Hematologic abnormalities in patients with hidradenitis suppurativa receiving adalimumab[J]. J Am Med Assoc Dermatol, 2024,160(6): 678-681.
[74]
ABU RACHED N, OCKER L, STOCKFLETH E, et al. Secukinumab is effective in a patient on haemodialysis for end-stage renal disease and severe hidradenitis suppurativa[J]. J Eur Acad Dermatol Venereol, 2024, 38(9):e753-e754.
2025年第46卷第9期
56
12
0
引用本文
BibTeX
文章信息
doi: 10.13683/j.wph.2025.09.001
  • 接收时间:2024-12-17
  • 首发时间:2026-11-09
  • 出版时间:2025-09-10
补充材料
相关文章
文章信息
作者
出版历史
  • 收稿日期:2024-12-17
基金
国家自然科学基金面上项目(82373506)
作者信息
    上海交通大学医学院附属仁济医院皮肤科,上海 200127

通讯作者:

鞠强,主任医师,研究方向:化脓性汗腺炎、痤疮。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/sjlcyw/CN/10.13683/j.wph.2025.09.001
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏